InvestorsHub Logo
Followers 8
Posts 2134
Boards Moderated 0
Alias Born 05/19/2021

Re: None

Wednesday, 05/22/2024 12:06:06 PM

Wednesday, May 22, 2024 12:06:06 PM

Post# of 2087
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $3.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 160.87% from the company’s previous close.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RNAZ News